Tectonic Advisors LLC Increases Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Tectonic Advisors LLC grew its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 7.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 81,286 shares of the biopharmaceutical company’s stock after buying an additional 5,580 shares during the quarter. Tectonic Advisors LLC’s holdings in Gilead Sciences were worth $7,508,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. boosted its position in Gilead Sciences by 8.6% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 434,165 shares of the biopharmaceutical company’s stock valued at $40,689,000 after buying an additional 34,549 shares during the period. Y.D. More Investments Ltd raised its stake in shares of Gilead Sciences by 43.3% in the fourth quarter. Y.D. More Investments Ltd now owns 1,602 shares of the biopharmaceutical company’s stock valued at $148,000 after acquiring an additional 484 shares in the last quarter. Hager Investment Management Services LLC purchased a new position in Gilead Sciences in the fourth quarter valued at $145,000. Stratos Investment Management LLC grew its stake in Gilead Sciences by 6.2% during the 4th quarter. Stratos Investment Management LLC now owns 2,895 shares of the biopharmaceutical company’s stock worth $267,000 after purchasing an additional 170 shares in the last quarter. Finally, Retirement Systems of Alabama increased its holdings in Gilead Sciences by 31.0% during the 4th quarter. Retirement Systems of Alabama now owns 998,307 shares of the biopharmaceutical company’s stock worth $92,214,000 after purchasing an additional 236,453 shares during the period. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, insider Merdad Parsey sold 164,211 shares of the company’s stock in a transaction dated Wednesday, November 27th. The shares were sold at an average price of $91.92, for a total transaction of $15,094,275.12. Following the transaction, the insider now directly owns 80,801 shares in the company, valued at approximately $7,427,227.92. This represents a 67.02 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Andrew D. Dickinson sold 248,645 shares of the business’s stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $92.76, for a total value of $23,064,310.20. Following the sale, the chief financial officer now directly owns 138,919 shares in the company, valued at $12,886,126.44. This trade represents a 64.16 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 572,824 shares of company stock worth $53,611,715 over the last three months. 0.29% of the stock is currently owned by corporate insiders.

Gilead Sciences Stock Down 0.4 %

Shares of Gilead Sciences stock opened at $97.99 on Wednesday. The company has a market cap of $122.12 billion, a P/E ratio of 1,088.78, a PEG ratio of 1.37 and a beta of 0.18. The firm has a fifty day moving average of $92.71 and a two-hundred day moving average of $86.32. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.10 and a current ratio of 1.26. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $99.45.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, beating analysts’ consensus estimates of $1.58 by $0.44. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The firm had revenue of $7.55 billion during the quarter, compared to the consensus estimate of $7.01 billion. During the same quarter last year, the firm earned $2.29 earnings per share. The firm’s revenue was up 7.0% compared to the same quarter last year. On average, analysts forecast that Gilead Sciences, Inc. will post 4.34 earnings per share for the current year.

Analyst Ratings Changes

GILD has been the subject of a number of analyst reports. Piper Sandler boosted their price objective on Gilead Sciences from $95.00 to $105.00 and gave the stock an “overweight” rating in a research report on Thursday, November 7th. Morgan Stanley upgraded shares of Gilead Sciences from an “equal weight” rating to an “overweight” rating and boosted their price target for the stock from $87.00 to $113.00 in a report on Friday, January 10th. Needham & Company LLC restated a “hold” rating on shares of Gilead Sciences in a report on Thursday, November 7th. Citigroup initiated coverage on shares of Gilead Sciences in a research note on Thursday, November 14th. They set a “buy” rating and a $125.00 target price for the company. Finally, Leerink Partners raised Gilead Sciences from a “market perform” rating to an “outperform” rating and increased their target price for the company from $74.00 to $96.00 in a report on Monday, October 21st. Eleven analysts have rated the stock with a hold rating, thirteen have issued a buy rating and four have issued a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $98.39.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.